Mark Lynch — ASN Events

Mark Lynch — ASN Events

, ,

Presentations this author is a contributor to:

Phase 3, randomized trial (CheckMate 017) of nivolumab (Nivo) vs docetaxel in advanced squamous (SQ) cell non-small cell lung cancer (NSCLC) (#214)

Longer-term follow-up of a phase 2 study (CheckMate 063) of nivolumab in patients with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC) (#200)